Cargando…
Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency
Autores principales: | Farkas, Henriette, Varga, Lilian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare Communications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873081/ https://www.ncbi.nlm.nih.gov/pubmed/27520465 http://dx.doi.org/10.1007/s13554-012-0004-3 |
Ejemplares similares
-
Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency
por: Farkas, Henriette, et al.
Publicado: (2012) -
Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010) -
Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
por: Farkas, Henriette, et al.
Publicado: (2011) -
Pediatric hereditary angioedema due to C1-inhibitor deficiency
por: Farkas, Henriette
Publicado: (2010) -
The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency
por: Zotter, Zsuzsanna, et al.
Publicado: (2014)